END OF YEAR GUIDANCE ON NOX66 CLINICAL DEVELOPMENT STRATEGY FOR 2018
• 3 current Phase 1 studies
• 4 multinational Phase 2/Phase 3 DARRT studies in 2018
• Aim to identify nature of Phase 3 studies by 3Q 2018
• Data reports scheduled for international cancer conferences throughout 2018
• Commitment to brain cancer study in 2018, including treatment of secondary brain cancers
• Abscopal Research Unit established.
Sydney, 21 December 2017: Noxopharm Limited (NOX:ASX) is pleased to provide guidance to the market on its clinical development strategy and indicative timetable for release of data in relation to its frontline drug candidate, NOX66.
For further information please download PDF attached:
Download this document
